QURE
Price
$25.46
Change
+$0.14 (+0.55%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
1.66B
88 days until earnings call
Intraday BUY SELL Signals
TRVI
Price
$13.70
Change
+$0.35 (+2.62%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
1.71B
111 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

QURE vs TRVI

Header iconQURE vs TRVI Comparison
Open Charts QURE vs TRVIBanner chart's image
uniQure
Price$25.46
Change+$0.14 (+0.55%)
Volume$24.92K
Capitalization1.66B
Trevi Therapeutics
Price$13.70
Change+$0.35 (+2.62%)
Volume$66.07K
Capitalization1.71B
QURE vs TRVI Comparison Chart in %
QURE
Daily Signal:
Gain/Loss:
TRVI
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
QURE vs. TRVI commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is QURE is a StrongBuy and TRVI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (QURE: $25.28 vs. TRVI: $13.35)
Brand notoriety: QURE and TRVI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: QURE: 26% vs. TRVI: 126%
Market capitalization -- QURE: $1.66B vs. TRVI: $1.71B
QURE [@Biotechnology] is valued at $1.66B. TRVI’s [@Biotechnology] market capitalization is $1.71B. The market cap for tickers in the [@Biotechnology] industry ranges from $107.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

QURE’s FA Score shows that 0 FA rating(s) are green whileTRVI’s FA Score has 1 green FA rating(s).

  • QURE’s FA Score: 0 green, 5 red.
  • TRVI’s FA Score: 1 green, 4 red.
According to our system of comparison, TRVI is a better buy in the long-term than QURE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

QURE’s TA Score shows that 6 TA indicator(s) are bullish while TRVI’s TA Score has 4 bullish TA indicator(s).

  • QURE’s TA Score: 6 bullish, 4 bearish.
  • TRVI’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, QURE is a better buy in the short-term than TRVI.

Price Growth

QURE (@Biotechnology) experienced а -9.59% price change this week, while TRVI (@Biotechnology) price change was +17.52% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

QURE is expected to report earnings on Mar 02, 2026.

TRVI is expected to report earnings on Mar 25, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TRVI($1.71B) and QURE($1.66B) have the same market capitalization . TRVI YTD gains are higher at: 224.029 vs. QURE (43.148). TRVI has higher annual earnings (EBITDA): -47.19M vs. QURE (-119.56M). QURE has more cash in the bank: 377M vs. TRVI (204M). TRVI has less debt than QURE: TRVI (891K) vs QURE (66.7M). QURE has higher revenues than TRVI: QURE (14.3M) vs TRVI (0).
QURETRVIQURE / TRVI
Capitalization1.66B1.71B97%
EBITDA-119.56M-47.19M253%
Gain YTD43.148224.02919%
P/E RatioN/AN/A-
Revenue14.3M0-
Total Cash377M204M185%
Total Debt66.7M891K7,486%
FUNDAMENTALS RATINGS
QURE vs TRVI: Fundamental Ratings
QURE
TRVI
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
47
Fair valued
PROFIT vs RISK RATING
1..100
10011
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
3635
P/E GROWTH RATING
1..100
88100
SEASONALITY SCORE
1..100
4450

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TRVI's Valuation (47) in the Pharmaceuticals Major industry is in the same range as QURE (57) in the Biotechnology industry. This means that TRVI’s stock grew similarly to QURE’s over the last 12 months.

TRVI's Profit vs Risk Rating (11) in the Pharmaceuticals Major industry is significantly better than the same rating for QURE (100) in the Biotechnology industry. This means that TRVI’s stock grew significantly faster than QURE’s over the last 12 months.

TRVI's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as QURE (100) in the Biotechnology industry. This means that TRVI’s stock grew similarly to QURE’s over the last 12 months.

TRVI's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as QURE (36) in the Biotechnology industry. This means that TRVI’s stock grew similarly to QURE’s over the last 12 months.

QURE's P/E Growth Rating (88) in the Biotechnology industry is in the same range as TRVI (100) in the Pharmaceuticals Major industry. This means that QURE’s stock grew similarly to TRVI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
QURETRVI
RSI
ODDS (%)
Bullish Trend 6 days ago
90%
Bearish Trend 6 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 6 days ago
80%
Bearish Trend 6 days ago
89%
Momentum
ODDS (%)
Bearish Trend 6 days ago
88%
Bullish Trend 6 days ago
87%
MACD
ODDS (%)
Bullish Trend 6 days ago
86%
Bullish Trend 6 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 6 days ago
87%
Bullish Trend 6 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 6 days ago
87%
Bullish Trend 6 days ago
84%
Advances
ODDS (%)
Bullish Trend 27 days ago
76%
Bullish Trend 10 days ago
82%
Declines
ODDS (%)
Bearish Trend 6 days ago
86%
Bearish Trend 14 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 6 days ago
76%
Bearish Trend 6 days ago
84%
Aroon
ODDS (%)
Bullish Trend 6 days ago
82%
Bullish Trend 6 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
QURE
Daily Signal:
Gain/Loss:
TRVI
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VPKIX17.11N/A
N/A
Vanguard Pacific Stock Index Instl
CFSIX20.66N/A
N/A
Touchstone Sands Capital Select Growth Y
RYLDX195.62N/A
N/A
Rydex Dow 2x Strategy A
AMGAX17.90N/A
N/A
Alger Mid Cap Growth A
HWVZX12.64N/A
N/A
Hotchkis & Wiley Sm Cp Divers Val Z

QURE and

Correlation & Price change

A.I.dvisor indicates that over the last year, QURE has been loosely correlated with NEVPF. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if QURE jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QURE
1D Price
Change %
QURE100%
-4.86%
NEVPF - QURE
50%
Loosely correlated
N/A
AXON - QURE
42%
Loosely correlated
+0.91%
LXEO - QURE
40%
Loosely correlated
-6.73%
MLTX - QURE
37%
Loosely correlated
-5.36%
SNGX - QURE
36%
Loosely correlated
+3.95%
More

TRVI and

Correlation & Price change

A.I.dvisor indicates that over the last year, TRVI has been loosely correlated with BIESF. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if TRVI jumps, then BIESF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRVI
1D Price
Change %
TRVI100%
+0.38%
BIESF - TRVI
42%
Loosely correlated
N/A
PTGX - TRVI
38%
Loosely correlated
-1.17%
QURE - TRVI
30%
Poorly correlated
-4.86%
XENE - TRVI
29%
Poorly correlated
-1.45%
ABSI - TRVI
28%
Poorly correlated
+0.16%
More